At the virtual ASCO 2020 conference, an update on DESTINY-Gastric01 Phase II trial provided a positive outlook for the future therapy of gastric cancer patients with the drug Enhertu (trastuzumab deruxtecan).
Enhertu is an antibody-drug conjugate made up of the HER-2 targeting trastuzumab antibody attached to a topoisomerase inhibitor payload. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
